Abivax Announces Results of its May 11, 2026 Annual General Meeting

Abivax (Nasdaq:ABVX) held its annual general meeting of shareholders on May 11, 2026, chaired by Board Chair Sylvie Grégoire.

Rhea-AI Summary

Abivax (Nasdaq:ABVX) held its annual general meeting of shareholders on May 11, 2026, chaired by Board Chair Sylvie Grégoire.

Shareholders approved all resolutions proposed by the Board, including 2025 financial statements, executive and director compensation policy, and delegations for financial transactions. Detailed voting results will be posted on Abivax's website.

Argus May 12 session

-0.61% close to close Open Argus

Details

News Market Reaction – ABVX

In the May 12 session, ABVX declined 0.61%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement confirms shareholders approved the 2025 financial statements, compensation policy,...

Analysis

This announcement confirms shareholders approved the 2025 financial statements, compensation policy, and delegations for financial transactions at the May 11, 2026 AGM. It follows recent financing, regulatory filings, and preparations for key scientific presentations. Investors may focus on how this governance continuity supports execution of Abivax’s clinical and financial plans, while monitoring upcoming data readouts and further regulatory disclosures for more material catalysts.

Key Figures

AGM date: May 11, 2026 Financial year approved: 2025

AGM date

May 11, 2026

Date of annual general meeting

Financial year approved

2025

Shareholders adopted 2025 financial statements

Historical Context

5 past events · Latest: May 05

5 events

1. May 05

   Royalty deal & offering

   24h Move

   +5.7%

   Repurchase of royalty certificates and $45M ADS offering at set price.

2. Apr 22

   Conference data plans

   24h Move

   -2.6%

   Announcement of nine obefazimod abstracts at Digestive Disease Week.

3. Apr 20

   AGM docs available

   24h Move

   -3.1%

   Publication of preparatory documents and agenda for May 11 AGM.

4. Apr 01

   Regulatory filings

   24h Move

   +3.0%

   Filing of Universal Registration Document and Form 20-F with regulators.

5. Mar 23

   Full-year results

   24h Move

   -4.5%

   2025 results with large net loss alongside strong cash position and updates.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Abivax Announces Results of its May 11, 2026 Annual General Meeting

PARIS, France – May 11, 2026 – 10:05 pm CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, held its annual general meeting of shareholders on May 11, 2026 (the “General Meeting”), which was chaired by Ms. Sylvie Grégoire, Chair of the Board of Directors of Abivax (the “Board”).

The shareholders have adopted all the resolutions proposed by the Board, and particularly the financial statements for the 2025 financial year, the compensation policy applicable to the Chairman, the Chief Executive Officer and the directors, as well as delegations granted to the Board related to financial transactions.

Details of the vote results will be available on the Company’s website (www.abivax.com).

About Abivax

Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Based in France and the United States, Abivax’s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis.

Contact:

Patrick Malloy
SVP, Investor Relations
Abivax SA
patrick.malloy@abivax.com
+1 847 987 4878

Attachment

• 2026_05_11_Abivax Announces Results of Annual General Meeting

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were the main results of Abivax (ABVX) 2026 annual general meeting?

Abivax reported that shareholders adopted all resolutions at the May 11, 2026 annual general meeting. According to Abivax, approvals covered 2025 financial statements, executive and director compensation policy, and delegations granted to the Board for financial transactions.

When did Abivax (ABVX) hold its 2026 annual general meeting of shareholders?

Abivax held its 2026 annual general meeting of shareholders on May 11, 2026. According to Abivax, the meeting took place in Paris and was chaired by Sylvie Grégoire, Chair of the Board of Directors of the company.

Did Abivax (ABVX) shareholders approve the 2025 financial statements at the May 11, 2026 AGM?

Yes, Abivax shareholders approved the company’s financial statements for the 2025 financial year at the May 11, 2026 AGM. According to Abivax, these statements were part of the resolutions proposed and adopted during the meeting.

What compensation policies were approved at Abivax (ABVX) 2026 annual general meeting?

Shareholders approved the compensation policy for the Chairman, Chief Executive Officer and directors at the 2026 AGM. According to Abivax, this policy was among the resolutions proposed by the Board and adopted by shareholders on May 11, 2026.

What financial transaction delegations were granted to Abivax (ABVX) Board on May 11, 2026?

At the May 11, 2026 AGM, shareholders granted delegations to the Board related to financial transactions. According to Abivax, these delegations authorize the Board to act on certain financing matters, with specific details to be consulted in the published resolutions.

Where can investors find detailed voting results of Abivax (ABVX) 2026 AGM?

Detailed voting results from Abivax’s May 11, 2026 annual general meeting will be available on the company’s website. According to Abivax, investors can consult these vote breakdowns online once they are published for public access.